Aspirin Demonstrates Cost Benefit Versus Statins In Heart Disease – Study
This article was originally published in The Tan Sheet
Executive Summary
Aspirin use for coronary heart disease prevention in a patient with a 5% five-year coronary risk costs less than one-fifth per event prevented than simvastatin (J&J/Merck's Zocor) in a patient at a 30% five-year risk, a British study found